<DOC>
	<DOCNO>NCT00941889</DOCNO>
	<brief_summary>The primary objective pilot study evaluate effect HPV vaccine Gardasil anal condylomata recurrence persistence rate HIV positive patient .</brief_summary>
	<brief_title>The Effect HPV Vaccination Recurrence Rates HIV Patients With Condylomata</brief_title>
	<detailed_description>A quadrivalent human papilloma virus ( HPV ) vaccine call Gardasil recently ( start study ) develop approved FDA prevention cervical HPV infection cervical cancer , associate infection virus . It unknown whether vaccine could also benefit treat anogenital wart , cause virus . This important clinically relevant question need answer . Anal wart high prevalence recurrence usually require extended lengths treatment follow-up , especially HIV population . At time , treatment anal wart require multiple surgery excise burden disease high . Therefore , disease represent significant expense patient health care system . Further , HPV virus cause anal wart associate anal cancer preliminary lesion know anal intraepithelial neoplasia ( AIN ) . This study touch two important , relevant costly healthcare issue : find well treatment common sexually transmitted disease country , help prevent anal cancer , often fatal disease .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>â‰¥18 year age ; HIV positive status ; CD4 &gt; 200 viral RNA &lt; 400 antiretroviral therapy ( HAART ) CD4 &gt; 350 HARRT ; presence anal wart require surgical excision/ablation . CD4 &lt; 200 and/or viral RNA &gt; 400 HAART CD4 &lt; 350 HAART ; low burden anal wart would require surgical excision/ablation ; previous vaccination HPV allergic reaction vaccine component ; patient currently pregnant ; patient previous diagnosis anal cancer ; patient incarcerate ; patient take immunomodulators ( i.e . interferon , interleukin , corticosteroid , etc . ) within last 90 day ; patient opportunistic infection last 90 day another intercurrent illness precludes safe enrollment study ; patient , judgment investigator , unlikely adhere protocol , either substance abuse psychiatric diagnosis , factor would affect compliance ; failure strictly comply vaccination schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HPV</keyword>
	<keyword>Anal condylomata</keyword>
	<keyword>Vaccine</keyword>
	<keyword>HIV positive patient</keyword>
	<keyword>Anal condylomata anal wart</keyword>
</DOC>